Acepodia has received FDA approval for the Investigational New Drug Application of ACE1831 to treat IgG4-related disease.

Retifanlimab, a groundbreaking therapeutic agent, is a fully humanized monoclonal antibody developed by Incyte Corporation.

Syndax has received FDA approval for Revuforj® (revumenib), marking it as the first menin inhibitor for treating adults and children with relapsed or refractory acute leukemia featuring a KMT2A translocation.

The drug VVD-130037 is a small molecule drug developed to target the KEAP1 x Nrf2 pathways in the treatment of neoplasms.

InnoCare reports the initial dosing of a participant in China's Phase III trial of the TYK2 inhibitor ICP-332 for treating atopic dermatitis.

Inotuzumab Ozogamicin, also known as Besponsa, is an antibody-drug conjugate (ADC) developed by Pfizer.

AC Immune Announces Favorable Preliminary Findings from Phase 2 Study of ACI-7104.056 Active Immunotherapy for Early Parkinson’s Disease.

Risperidone is a small molecule drug that acts on the 5-HT2A and D2 receptors.

Blenrep demonstrates improved overall survival in the DREAMM-7 phase III trial for relapsed/refractory multiple myeloma.

Antisense oligonucleotide (ASO) drugs represent a significant branch of the small nucleic acid therapeutic field, functioning as molecules that regulate gene expression through specific binding to mRNA.

Levicept Unveils Promising Phase II Results for LEVI-04, a New Neurotrophin-3 Inhibitor, in Treating Moderate to Severe Osteoarthritis at ACR Convergence 2024.

Suzetrigine is a small molecule drug developed by Vertex Pharmaceuticals, Inc. It is designed to target the Nav1.8 channel.